Optimizing Cancer-related Anemia Outcomes in the Community Setting: Interprofessional Approaches and Evidence-supported Strategies for Improving Care with Intravenous Iron

This podcast focuses on educating, informing, and empowering clinicians involved in the care of patients with triple-negative breast cancer (TNBC) to positively impact the racial/ethnic disparities that negatively impact Black women. Our faculty will explore strategies that promote equitable care and outcomes for all patients; evaluate the role of antibody-drug conjugates (ADCs) in TNBC; and discuss the rapidly evolving clinical practice guidelines, safety and efficacy data of novel therapies, and practical ADC management strategies to anticipate and mitigate adverse events. To claim credit, visit: https://www.ceconcepts.com/activity/actionable-strategies-in-community-oncology-to-achieve-equity-in-triple-negative-breast-cancer-3/

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here:  https://www.ceconcepts.com/activity/primary-care-perspectives-on-obesity-embracing-novel-agents-to-optimize-patient-outcomes-2/

This podcast reviews the etiology and epidemiology of obesity, as well as prominent unmet needs and barriers to treatment optimization as a means of providing foundational context for learners. Expert faculty will then lead attendees on an immersive, deep dive through the established paradigm and the preponderance of emerging data for novel weight-loss therapeutics, most notably the GLP-1 agonists and the GLP-1/GIP agonists. The session will conclude with a case-based segment, in which attendees will get to apply the principles they have learned to real-world clinical scenarios, address practical weight-loss challenges, and highlight the instrumental role of the primary care physician as a gatekeeper for the obesity management team.  Request credit here: https://www.ceconcepts.com/activity/primary-care-perspectives-on-obesity-embracing-novel-agents-to-optimize-patient-outcomes-2/

Supported through an independent educational grant from Lilly.

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here:  https://www.ceconcepts.com/igan-ee-podcast

This activity will take learners on a deep dive into the pathophysiology of proteinuric glomerular disease, with an incisive focus on IgA nephropathy (IgAN). Expert faculty will review the totality of emerging evidence for novel therapeutics in IgAN, including an appraisal of consensus guidelines and regulatory updates. Finally, the session will conclude with a case-based segment wherein attendees will get to apply the principles they’ve learned to real-world clinical scenarios.

Supported through an independent educational grant from Travere.

This educational session will comprehensively evaluate the current state of the bladder cancer management paradigm and investigate the emergence of new data across the totality of the disease continuum, with a particular emphasis on evidence-based treatment sequencing and the role of antibody-drug conjugates (ADCs) in subsequent lines of therapy for advanced disease. To conclude the session, activity attendees will get to apply the therapeutic principles they’ve learned to real-world clinical scenarios which will focus on patient-centric treatment selection and sequencing, as well as recognition, mitigation, and management of treatment-related adverse events.

• 1.50 AMA PRA Category 1 Credit™
• 1.50 Participation

Collect credit: https://www.ceconcepts.com/gu-cancer23-podcast

This educational activity will meet nephrology nurses where they are and provide them with expert insights into CKD-aP prevalence, patient burden, therapeutic rationale, and pivotal principles for safely and effectively integrating novel treatments into practice. The role of the nurse as a premier patient-facing care provider will be emphasized throughout, and notable focus will be placed on CKD-aP symptom recognition, patient education, drug administration, and toxicity management.

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/navigating-ckd-podcast#group-tabs-node-course-default1

To facilitate timely diagnosis and rapid treatment initiation for anemia in CKD, the multidisciplinary and interprofessional CKD-anemia treatment team should be aware of the significant impact of anemia on patient quality of life, progression of CKD, and cardiovascular events. Erythropoietin-stimulating agents (ESAs) are associated with significant cardiovascular safety-related concerns, but the emergence of the oral hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) may improve erythropoiesis without the undesirable downstream effects of ESAs. However, HIF-PHIs place in therapy has not yet been fully elucidated. Here, join the interprofessional team of Dr. Ajay Singh, Dr. Jane Davis, and Dr. Calvin Meaney as they explore an incisive review of current CKD-anemia treatment and diagnostic challenges, as well as the evidentiary base for HIF-PHI utilization in CKD-anemia that establishes context for the future of these agents. In conclusion, a practical discussion of real-world patient case scenarios will be presented, to provide learners with context of the multiple comorbidities, complexities, diagnostic challenges, and barriers to appropriate treatment of CKD-anemia.

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/hk-ch-podcast 

Learning Objectives

• Appraise key mechanisms of potassium homeostasis and review patient-centric risk factors for hyperkalemia.
• Discuss the prevalence and clinical gravity of hyperkalemia, with emphasis on acute care challenges and the morbidity/mortality impact of suboptimal renin-angiotensin-aldosterone system inhibitor (RAASi) utilization in the chronic setting.
• Evaluate novel K+ binder (patiromer and sodium zirconium cyclosilicate [SZC]) pharmacology, safety and efficacy profiles, and differential clinical utility across the hyperkalemia treatment continuum.
• Examine evolving clinical trial data in support of patiromer and SZC for hyperkalemia management, with a particular focus on usage in acute care and in-hospital settings.
• Use a case-based approach to design treatment strategies using novel K+ binders that the interprofessional care team can employ to improve hyperkalemia outcomes in the hospital.

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/sitc22-podcast

This session will review the totality of emerging evidence for immune checkpoint inhibitors (ICIs) in the hepatocellular carcinoma (HCC) and biliary tract cancer (BTC) management calculus. Faculty will highlight the paradigmatic change ICIs have achieved, emphasize key teaching points for real-world use, and evaluate adaptive clinical trial designs and study schemas being used to investigate ICI-based treatment regimens in HCC and BTC on a prospective basis.

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/iv-iron-expert-exchange-podcast

In this Expert Exchange-based format, activity attendees will be immersed in a lively discussion between key thought leaders in the world of HF. Expert discussion will include an exploration of clinical trial data for intravenous (IV) iron therapies in HF and recently-updated expert consensus HF management guidelines, with emphasis on the emerging role of IV iron on improved clinical endpoints in HFrEF. Key teaching points up for debate include the safety and efficacy profiles of next-generation IV iron products, established and emerging clinical trial data in HF, and a comparative analysis of currently-available IV iron products.

To receive up to 2.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/2022chest-podcast

This dynamic live symposium, led by top experts in the field of pulmonary medicine and NSCLC, will take attendees on a deep dive into the sentinel role of the pulmonologist in the NSCLC management paradigm, exploring adaptive mechanisms to optimize collaborative strategies in a patient centric manner.

Learning Objectives

• Review the sentinel placement of the pulmonologist in the management of NSCLC, including their principal role in diagnostics, disease staging, and molecular testing.
• Evaluate clinical and patient-value driven factors that may help inform nodule evaluation and diagnostic strategies for pulmonologists, thus ensuring “the right tissue in the right amount from the right place for the right patient.”
• Demonstrate knowledge of guideline recommendations and practical considerations for the use of EBUS-TNBA techniques by pulmonologists, emphasizing the fundamentals of safely and effectively obtaining adequate tissue for diagnosis and molecular characterization.
• Describe the evolving role of targeted therapy and immunotherapy in NSCLC and analyze currently FDA-approved therapeutics across the NSCLC disease continuum, highlighting the role of molecular testing for guiding treatment and individualizing patient care.
• Explore the established utility of next-generation sequencing (NGS) and discuss the potential for emerging “next-generation” biomarkers in the NSCLC management paradigm.
• Apply patient-centric, evidence-supported collaborative care strategies to real-world, case-based scenarios in order to elucidate the pivotal role of the pulmonologist on the multidisciplinary team across the NSCLC continuum of care.

Presented by Creative Educational Concepts, LLC.

Supported through an independent educational grant from AstraZeneca.